Loading

DEVELOPING ONCOLOGY THERAPEUTICS
WITH GREATER SAFETY AND EFFICACY

OUR MISSION

Hillstream BioPharma Inc. Inc. is focused developing targeted oncology therapeutics as well as in-licensing and acquiring pharmaceutical products which play an important role in helping millions of patients lead longer and healthier lives.
We are dedicated to serving our patients and shareholders as we create value.
CURRENT PIPELINE
HSB-407

Hillstream is developing a novel proprietary nanoparticle formulation of bortezomib at the currently approved dose, yet with an improved side effect profile, for e.g.HSB-407 can lower the incidence of peripheral neuropathy from the current incidence of at least 37%. Combinations with immuno-oncology / PD-1 therapies in the same nanoparticle can further improve safety and efficacy of both drugs synergistically.

HSB-408

Hillstream is also developing a novel proprietary nanoparticle formulation of bortezomib with up to a 50% increase from the currently approved dose of 1.3 mg/m² with significantly improved efficacy and much lower side effects such as peripheral neuropathy.
There is significant opportunity to gain market share from bortezomib prescriptions as improved safety (HSB-407) and subsequently potential to dramatically improve efficacy using higher doses (HSB-408), in the US market where current sales are annualizing at approximately $1.2 billion.

ABOUT HILLSTREAM

Hillstream BioPharma Inc. is a development stage biopharmaceutical company dedicated to developing cancer therapeutics to help patients with unmet medical needs. We seek to develop 505(b)(2) therapeutics, in-license, identify, develop and commercializeproducts in oncology. We plan to build upon our portfolio through in-licensing and leveraging proprietary in-licensed nanoparticle technology.




Business Opportunities

Hillstream BioPharma Inc. delivers solutions through our focus on reformulating oncological products, providing quality and safety and improving the lives of our patients. Looking ahead, Hillstream plans continue to create a robust pipeline of products.
Please contact us about a potential business development or collaboration opportunity at: BUSDEV@hillstreambio.com